Depressions Agreement with Evotec order EVT 101 for treatment-resistant depression developRoche and Evotec today announced that they of an agreement entered Phase II clinical development of EVT 101 in patients with treatment-resistant depression. The potential value of this transaction exceeds 300 million.
‘.. Evotec will also phase I safety and tolerability studies for EVT 103, the next generation of EVT 101 Roche will fully fund these development programs. In addition, for the option to buy back the entire EVT 100 family of compounds, Roche has agreed to pay Evotec an upfront payment of USD 10 million. ,, Chief Financial Officer of Evotec, said: ‘This product development with Roche clear evidence of the value Evotec with the EVT 100 compound family has created in recent years, benefiting patients and therefore the shareholders We are pleased. Be be with Roche and has obvious advantages for both parties.Since it expands, cover the CoreValve the affected natural valve leaflets. Course of the procedure patients were on a bypass pump for an average of 30 or 40 minutes the blood flow the flow of blood through the aorta easy placement easy placement the replacement valve.. To evaluate the CoreValve system, Anita Asgar, and colleagues on the the Montreal Heart Institute recruits seventeen elderly subjects a severely narrowed aortic , all of which had been have down for surgery because of other health problems became.